Molindone for schizophrenia and severe mental illness

Bagnall, A-M; Fenton, Mark; Lewis, Ruth; Leitner, M; Kleijnen, Jos

doi:10.1002/14651858.cd002083

Cited by 12 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has a similar receptor binding profile to quetiapine, with very low binding to all receptors. 13 This profile includes lower affinity for the D 2 receptors compared to haloperidol and chlorpromazine, as well as lower antagonism at the H 1 receptors, which might explain molindone's lower tendency to cause weight gain.…”

mentioning

confidence: 99%

Long-Acting Injectable Risperidone and Hospital Readmission

Chang

Tang²,

Tsai

et al. 2009

J. Clin. Psychiatry

View full text Add to dashboard Cite

Sir: Poor compliance with antipsychotic medication, which would potentially lead to disease relapse, has been challenging for psychiatrists when treating schizophrenia.1 Long-acting injection of antipsychotics is an appropriate alternative, since better compliance improves treatment outcomes. Mirror-image studies, in which each patient acts as his/her own control, of long-acting injection of conventional antipsychotics have shown significant decreases in numbers of hospitalizations and days of hospitalization. The development of atypical antipsychotics has provided a new treatment paradigm based on their superior tolerability, if not efficacy. Risperidone long-acting injection (RLAI) is the first licensed long-acting injectable atypical antipsychotic agent and has recently been reported cost-effective by reducing total admission number and inpatient days in a communitybased inpatient setting.3 To our knowledge, a national claimbased database has never been used in any mirror-image study for RLAI.Method. The data source used for this 6-month mirror image study was the Psychiatric Inpatients Medical Claims Data (PIMC) from the National Health Research Institute, Taiwan. The PIMC compiled all the health care utilization records during 1996-2006 for patients who had at least 1 psychiatric hospitalization during 1996-2001. The inclusion criteria required that patients (1) could be observed at least 6 months after the first dose of RLAI, (2) had a primary diagnosis of schizophrenia, and (3) were continuously treated with RLAI for at least 6 months. Patients who received at least 75 mg RLAI total for a 3-month time period were considered continuously treated. The differences in number of acute admissions, hospital days, and emergency room visits between the pre-and post-RLAI periods were compared.Results. A total of 253 from 91,104 patients met the inclusion criteria. As compared to the 6-month pre-RLAI period, the total number of acute admissions was reduced by 35% (136 vs. 88 times, p = .0007), and total hospital stays were reduced by 47% (5856 vs. 3080 days, p = .0002) in the 6-month post-RLAI period. A reduced number of emergency room visits was also observed (80 vs. 67 times) but was not significantly different (p = .24). Since the average hospital stay in acute psychiatric settings was 33 days in Taiwan (data on file; Department of Health, Executive of Yuan, Taiwan; 2007), a secondary analysis to eliminate prolonged hospitalization was conducted by excluding patients who stayed longer than 90 days per admission in the pre-RLAI period. The case number was therefore slightly decreased (N = 237), but the differences in acute admissions (115 vs. 80, p = .0010) and hospital days (3701 vs. 2160 days, p = .0026) remained significant.

show abstract

mentioning

confidence: 99%

Long-Acting Injectable Risperidone and Hospital Readmission

Chang

Tang²,

Tsai

et al. 2009

J. Clin. Psychiatry

View full text Add to dashboard Cite

show abstract

Valproate for schizophrenia

Schwarz

Volz

et al. 2008

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Based on currently available randomised trial-derived evidence, there are no data to support or to refute valproate as a sole agent for schizophrenia. There is some evidence for positive effects on aggression and tardive dyskinesia, but given that these results were based on only a single small study they cannot be considered robust. Given the paucity of the available database further large, simple well-designed and reported trials are necessary. Ideally these would focus on people with schizophrenia and aggression, on those with treatment resistant forms of the disorder and on those with schizoaffective disorders.

show abstract

Risperidone versus olanzapine for schizophrenia

Jayaram¹,

Hosalli²

2005

The Cochrane Database of Systematic Reviews (Protocol)

View full text Add to dashboard Cite

Molindone for schizophrenia and severe mental illness

Cited by 12 publications

References 24 publications

Long-Acting Injectable Risperidone and Hospital Readmission

Long-Acting Injectable Risperidone and Hospital Readmission

Valproate for schizophrenia

Risperidone versus olanzapine for schizophrenia

Contact Info

Product

Resources

About